NL8502713A - Water-oplosbare farmaceutische preparaten, welke zouten van (-)cis-1,2-epoxypropylfosfonzuur met aminozuren bevatten. - Google Patents

Water-oplosbare farmaceutische preparaten, welke zouten van (-)cis-1,2-epoxypropylfosfonzuur met aminozuren bevatten. Download PDF

Info

Publication number: NL8502713A
Authority: NL; Netherlands
Prior art keywords: water; cis; pharmaceutical preparations; amino acids; soluble pharmaceutical
Prior art date: 1984-10-05

Application number

NL8502713A

Other languages

English (en)

Dutch (nl)

Original Assignee

Seuref Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-10-05

Filing date

1985-10-04

Publication date

1986-05-01

1985-10-04 Application filed by Seuref Ag filed Critical Seuref Ag

1986-05-01 Publication of NL8502713A publication Critical patent/NL8502713A/nl

Links

150000001413 amino acids Chemical class 0.000 title claims description 6
239000000825 pharmaceutical preparation Substances 0.000 title claims description 4
150000007530 organic bases Chemical class 0.000 claims description 10
150000003839 salts Chemical class 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 6
-1 1,1-dimethyl-2-amino amino, 2-aminobutanol Chemical compound 0.000 claims description 3
239000004475 Arginine Substances 0.000 claims description 3
150000001414 amino alcohols Chemical class 0.000 claims description 3
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
150000001875 compounds Chemical class 0.000 description 5
239000000243 solution Substances 0.000 description 5
235000001014 amino acid Nutrition 0.000 description 4
230000003115 biocidal effect Effects 0.000 description 4
YMDXZJFXQJVXBF-STHAYSLISA-N fosfomycin Chemical compound C[C@@H]1O[C@@H]1P(O)(O)=O YMDXZJFXQJVXBF-STHAYSLISA-N 0.000 description 4
239000000203 mixture Substances 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
JCBPETKZIGVZRE-UHFFFAOYSA-N 2-aminobutan-1-ol Chemical compound CCC(N)CO JCBPETKZIGVZRE-UHFFFAOYSA-N 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
229960003237 betaine Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
230000003750 conditioning effect Effects 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000007911 effervescent powder Substances 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000036512 infertility Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
238000000034 method Methods 0.000 description 1
239000008183 oral pharmaceutical preparation Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000723 toxicological property Toxicity 0.000 description 1
230000010415 tropism Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
- C07F9/65502—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a three-membered ring
- C07F9/65505—Phosphonic acids containing oxirane groups; esters thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Dermatology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Oil, Petroleum & Natural Gas (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

NL8502713A 1984-10-05 1985-10-04 Water-oplosbare farmaceutische preparaten, welke zouten van (-)cis-1,2-epoxypropylfosfonzuur met aminozuren bevatten. NL8502713A (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CH479184		1984-10-05
CH4791/84A CH660305A5 (de)	1984-10-05	1984-10-05	Wasserloesliche pharmazeutische zusammensetzungen auf der basis von salzen der (-)cis-1,2-epoxypropylphosphonsaeure mit aminosaeuren.

Publications (1)

Publication Number	Publication Date
NL8502713A true NL8502713A (nl)	1986-05-01

Family

ID=4282601

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL8502713A NL8502713A (nl)	1984-10-05	1985-10-04	Water-oplosbare farmaceutische preparaten, welke zouten van (-)cis-1,2-epoxypropylfosfonzuur met aminozuren bevatten.

Country Status (12)

Country	Link
US (1)	US4783449A (ko)
JP (1)	JPS62223122A (ko)
KR (1)	KR860003011A (ko)
AT (1)	AT383735B (ko)
BE (1)	BE903368A (ko)
CH (1)	CH660305A5 (ko)
DE (1)	DE3535355A1 (ko)
ES (1)	ES8608861A1 (ko)
FR (1)	FR2572934B1 (ko)
GB (1)	GB2165153B (ko)
IT (1)	IT1201478B (ko)
NL (1)	NL8502713A (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4003054A1 (de) *	1990-02-02	1991-08-08	Hoechst Ag	Verwendung von benzylphosphonsaeurederivaten zur behandlung von durch viren verursachte krankheiten
ITMI20021725A1 (it) *	2002-08-01	2002-10-31	Zambon Spa	Composizioni farmaceutiche ad attivita' antibiotica.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH310498A (de) *	1951-11-14	1955-10-31	Waldhof Zellstoff Fab	Verfahren zur Stabilisierung von Alkalisalzen von Adenosinpolyphosphorsäuren.
DE1492204A1 (de) *	1962-04-14	1969-07-17	Uhlenbroock Dr Med Kurt	Verfahren zur Herstellung von stabilen,waessrigen Injektionsloesungen von Monophenyl-4-butylpyrazolidin-Verbindungen
DE1767212B1 (de) *	1967-04-13	1971-05-06	Sumitomo Chemical Co	Verfahren zur Herstellung injizierbarer Arzneimittel
BE756953A (fr) *	1969-10-02	1971-04-01	Merck & Co Inc	Potentialisation d'antibiotiques
IT1161974B (it) *	1978-02-02	1987-03-18	Italchemi Spa	Derivti dell acido cis.i 2 epossipropilfosfonico loro procedimento di preparazione e composizioni farmaceutiche che li contengono
IT1112282B (it) *	1978-07-19	1986-01-13	Zambon Spa	Bis-(2-ammonio-2-idrossimetil-1,3-propandiolo)(2r-cis)-(3-metilossiranil)fosfonato
IT1097578B (it) *	1978-07-31	1985-08-31	Italchemi Spa	Metodo per la preparazione di sali dell'acido (-)
IT1124610B (it) *	1979-10-18	1986-05-07	Zambo Spa	Mono(2-ammonio-2-idrossimetil-1,3-propandiolo) (2r-cis)-(o-metilossiranil)fosfonato
AU565425B2 (en) *	1982-11-01	1987-09-17	Stichting Katholieke Universiteit	Sparsomycin (sc-rs) derivative

1984
- 1984-10-05 CH CH4791/84A patent/CH660305A5/de not_active IP Right Cessation
1985
- 1985-10-02 JP JP60219970A patent/JPS62223122A/ja active Pending
- 1985-10-03 DE DE19853535355 patent/DE3535355A1/de not_active Withdrawn
- 1985-10-03 AT AT0286985A patent/AT383735B/de not_active IP Right Cessation
- 1985-10-03 US US06/783,747 patent/US4783449A/en not_active Expired - Fee Related
- 1985-10-04 ES ES547624A patent/ES8608861A1/es not_active Expired
- 1985-10-04 GB GB08524551A patent/GB2165153B/en not_active Expired
- 1985-10-04 IT IT22366/85A patent/IT1201478B/it active
- 1985-10-04 NL NL8502713A patent/NL8502713A/nl not_active Application Discontinuation
- 1985-10-04 BE BE2/60806A patent/BE903368A/nl not_active IP Right Cessation
- 1985-10-05 KR KR1019850007327A patent/KR860003011A/ko not_active Application Discontinuation
- 1985-10-07 FR FR8514799A patent/FR2572934B1/fr not_active Expired

Also Published As

Publication number	Publication date
KR860003011A (ko)	1986-05-19
ATA286985A (de)	1987-01-15
ES8608861A1 (es)	1986-09-01
GB2165153B (en)	1988-03-23
GB2165153A (en)	1986-04-09
IT8522366A0 (it)	1985-10-04
DE3535355A1 (de)	1986-04-17
BE903368A (nl)	1986-02-03
JPS62223122A (ja)	1987-10-01
IT1201478B (it)	1989-02-02
FR2572934B1 (fr)	1988-10-28
FR2572934A1 (fr)	1986-05-16
GB8524551D0 (en)	1985-11-06
AT383735B (de)	1987-08-10
US4783449A (en)	1988-11-08
CH660305A5 (de)	1987-04-15
ES547624A0 (es)	1986-09-01

Legal Events

Date	Code	Title	Description
1986-06-02	BA	A request for search or an international-type search has been filed
1986-06-16	CNR	Transfer of rights (patent application after its laying open for public inspection)	Free format text: SCHERING S.P.A.
1987-04-01	BB	A search report has been drawn up
1987-10-16	CNR	Transfer of rights (patent application after its laying open for public inspection)	Free format text: GENTILI S.P.A. ISTITUTO -
1992-12-01	BV	The patent application has lapsed

Publication	Publication Date	Title
CH616080A5 (ko)	1980-03-14
BG64584B1 (bg)	2005-08-31	Фармацевтични състави, съдържащи вориконазол
DE2043933B2 (de)	1977-09-08	N-(beta-naphthylaminomethyl)-aminocarbonsaeuren sowie diese enthaltende arzneimittel
JPH0643425B2 (ja)	1994-06-08	ビンポセチンのくえん酸塩及びそれを含む薬剤
US6242492B1 (en)	2001-06-05	N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid in iron chelating therapy
EP0226591B1 (en)	1992-09-23	Anti-tumor compositions containing the reaction product of a cytotoxic aldehyde with penicillamine and their use for the manufacture of medicaments
US5116949A (en)	1992-05-26	Benzoyl urea compound-albumin complex
FR2584405A1 (fr)	1987-01-09	Sels de furosemide, composition pharmaceutique les contenant et leur procede de preparation
NL8502713A (nl)	1986-05-01	Water-oplosbare farmaceutische preparaten, welke zouten van (-)cis-1,2-epoxypropylfosfonzuur met aminozuren bevatten.
GB1599612A (en)	1981-10-07	Antiviral agent and treatment of viral infections
CA1336072C (en)	1995-06-27	Therapeutic composition for hepatic encephalopathy
NL8502712A (nl)	1986-05-01	Water-oplosbare farmaceutische preparaten, welke zouten van (-)cis-1,2-epoxypropylfosfonzuur met aminozuren bevatten.
CA2064999A1 (fr)	1991-02-26	Derives de la 5-amino-1,2,3,4 tetrahydro-acridine et utilisation comme medicaments
CA1147752A (en)	1983-06-07	Isoprenylamines
US4937233A (en)	1990-06-26	Method of treating herpes eye infections with 5-propyl-2'-deoxyuridine
JP3000490B2 (ja)	2000-01-17	抗白癬菌剤
JPS58146509A (ja)	1983-09-01	医薬組成物
US5484785A (en)	1996-01-16	Salts of a quinolone-carboxylic acid
JPH0587073B2 (ko)	1993-12-15
JPH0539226A (ja)	1993-02-19	サイトメガロウイルス感染症用薬剤
FR2455598A1 (fr)	1980-11-28	Nouveaux derives 5- (2- ((2,3-dihydro-1,4-benzodioxanne-2-ylmethyl)- amino)-1- hydroxyethyl)-2-hydroxybenzoiques, utiles notamment comme agents bloquants des recepteurs adrenergiques a et b, et leur procede de preparation
JPH0267283A (ja)	1990-03-07	６‐メルカプトプリン誘導体およびその製法
JPH05201876A (ja)	1993-08-10	Ｆｋ５６５の副作用軽減剤
JPH0435444B2 (ko)	1992-06-11
JPH0853352A (ja)	1996-02-27	３ーオキシゲルミルプロピオン酸化合物を主成分とする動物用薬剤